<DOC>
	<DOC>NCT01057810</DOC>
	<brief_summary>The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo</brief_summary>
	<brief_title>Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Metastatic prostate cancer Asymptomatic or minimally symptomatic Progression during hormonal therapy Eastern Cooperative Oncology Group (ECOG) Performance Status 01 Liver, lung or brain metastases Prior immunotherapy or chemotherapy for metastatic prostate cancer Autoimmune disease HIV, Hepatitis B, or Hepatitis C infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>